Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.54 |
| ▸ | HTR2A | P28223 | 5/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29768449 | 1.00 | SLC6A4 (0.54) | SLC6A4HTR2AKCNH2CA12CA1 | |
| SCHEMBL11175966 | 0.86 | HSP90AA1 (0.57) | SLC6A4HTR2AKCNH2CA12CA1 | |
| SCHEMBL31287771 | 0.86 | HSP90AA1 (0.57) | SLC6A4HTR2AKCNH2CA12CA1 | |
| SCHEMBL19785375 | 0.82 | HSP90AA1 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12325069 | 0.82 | HSP90AA1 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8536628 | 0.81 | CA12 (0.42) | SLC6A4HTR2AKCNH2CA12CA1 | |
| SCHEMBL2092168 | 0.81 | AHR (0.61) | CA12CA1CA2CA7CA9 | |
| Potassium Ion SCHEMBL6136043 | 0.81 | CA12 (0.42) | SLC6A4HTR2AKCNH2CA12CA1 | |
| SCHEMBL130126 | 0.80 | MCL1 (0.52) | SLC6A4HTR2AKCNH2CA12CA1 | |
| SCHEMBL197088 | 0.80 | CA12 (0.62) | SLC6A4HTR2ACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2178373-B1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN INC (US) | 2013-01-23 | — | — | EP | claimed |
| EP-2536718-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | Icagen, Inc. (US) | 2012-12-26 | — | — | EP | claimed |
| US-8058274-B2 | Heterocycles as potassium channel modulators | ICAGEN, INC. (US) | 2011-11-15 | — | — | US | claimed |
| WO-2011102964-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2011-08-25 | — | — | WO | claimed |
| EP-2178373-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | Icagen, Inc. (US) | 2010-04-28 | — | — | EP | claimed |
| US-20090062290-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2009-03-05 | — | — | US | claimed |
| WO-2009026254-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2009-02-26 | — | — | WO | claimed |
| EP-1917239-A1 | FLUOROPROSTAGLANDINS NITRODERIVATIVES | Pfizer, Inc. (US) | 2008-05-07 | — | — | EP | claimed |
| WO-2007000642-A1 | FLUOROPROSTAGLANDINS NITRODERIVATIVES | PFIZER INC. (US) | 2007-01-04 | — | — | WO | claimed |
| EP-0930296-B2 | FLUORINATED PROSTAGLANDIN DERIVATIVES AND MEDICINES | ASAHI GLASS CO LTD (JP) | 2005-11-02 | — | — | EP | claimed |
| EP-0930296-B1 | FLUORINATED PROSTAGLANDIN DERIVATIVES AND MEDICINES | ASAHI GLASS CO LTD (JP) | 2002-07-24 | — | — | EP | claimed |
| EP-0930296-A1 | FLUORINATED PROSTAGLANDIN DERIVATIVES AND MEDICINES | ASAHI GLASS COMPANY LTD. (JP) | 1999-07-21 | — | — | EP | claimed |
| US-20240368078-A1 | ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2024-11-07 | — | — | US | disclosed |
| EP-4313313-A1 | ARYL HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. Shaw Research, LLC (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117337280-A | Aryl heterocyclic compounds as Kv1.3 potassium SHAKER channel blockers | D·E·萧尔研究有限责任公司 | 2024-01-02 | — | — | CN | disclosed |
| EP-3507275-B1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-4175197-A | 1,3,4-Trisubstituted-4-aryl-1,4,5,6-tetra-hydropyridines | ELI LILLY AND COMPANY (US) | 1979-11-20 | — | — | US | disclosed |
| US-4159272-A | Process for 2-chlorosulfinylazetidin-4-ones | ELI LILLY AND COMPANY (US) | 1979-06-26 | — | — | US | disclosed |
| US-4115400-A | 1-Azoniabicyclo[3.1.0]hexanes | ELI LILLY AND COMPANY (US) | 1978-09-19 | — | — | US | disclosed |
| US-4081450-A | 1,3,4-Trisubstituted-4-arylpiperidines and their preparation | ELI LILLY AND COMPANY (US) | 1978-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062290-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK2, KCNK17 | SLC6A4 1073/4885HTR2A 1109/4885KCNH2 6/4885 |
| US-20240368078-A1 | ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNH2, KCNH3 | SLC6A4 1100/4885HTR2A 1780/4885KCNH2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.